Long-Term Low-Dose Pyrimethamine Use for the Prevention of Ocular Toxoplasmosis Recurrences: A Cohort Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Informa Healthcare Country of Publication: England NLM ID: 9312169 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-5078 (Electronic) Linking ISSN: 09273948 NLM ISO Abbreviation: Ocul Immunol Inflamm Subsets: MEDLINE
    • Publication Information:
      Publication: London : Informa Healthcare
      Original Publication: Buren, The Netherlands : Aeolus Press, c1993-
    • Subject Terms:
      Toxoplasmosis, Ocular*/prevention & control ; Toxoplasmosis, Ocular*/drug therapy ; Toxoplasmosis, Ocular*/diagnosis ; Toxoplasmosis, Ocular*/parasitology ; Pyrimethamine*/therapeutic use ; Recurrence* ; Secondary Prevention*/methods; Humans ; Female ; Male ; Adult ; Middle Aged ; Toxoplasma/immunology ; Young Adult ; Follow-Up Studies ; Adolescent ; Antiprotozoal Agents/therapeutic use ; Dose-Response Relationship, Drug ; Antibodies, Protozoan/blood ; Aged ; Leucovorin/therapeutic use ; Immunoglobulin G/blood
    • Abstract:
      Purpose: To describe the effect of long-term, low-dose pyrimethamine for the prevention of ocular toxoplasmosis (OT) recurrences.
      Methods: Sixty-three consecutive patients with inactive ocular toxoplasmosis and positive toxoplasma IgG serology were included. Pyrimethamine (25 mg) + folinic acid (15 mg) were administered every other day (three times weekly) for 12 months. Eighteen patients received the treatment for an additional six months as part of an extension study.
      Results: Thirty-eight patients (60.3%, n  = 63) were female; 38 (60.3%) had a previous history of recurrence and 37 (58.7%) had active OT within the preceding 12 months. Three (4.8%) patients had unilateral recurrences at 8, 12 and 18 months after starting intermittent pyrimethamine treatment. Five patients (7.9%) were discontinued due to hematological, renal and hepatic changes. Treatment was considered successful in 42 patients (84%).
      Conclusion: Long-term, low-dose pyrimethamine can be considered as a treatment option for the prevention of ocular toxoplasmosis recurrence in selected patients, with only a few, mild and reversible systemic adverse events.
    • Contributed Indexing:
      Keywords: Ocular toxoplasmosis; pyrimethamine; relapses; toxoplasmosis; treatment
    • Accession Number:
      Z3614QOX8W (Pyrimethamine)
      0 (Antiprotozoal Agents)
      0 (Antibodies, Protozoan)
      Q573I9DVLP (Leucovorin)
      0 (Immunoglobulin G)
    • Publication Date:
      Date Created: 20240305 Date Completed: 20241024 Latest Revision: 20241024
    • Publication Date:
      20241025
    • Accession Number:
      10.1080/09273948.2024.2321270
    • Accession Number:
      38441575